Cell therapy for type 1 diabetes
Islet transplantation and stem cell-derived beta cells.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 0, 2, 0, 1, 5.
All papers from the last 12 months
148 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Retrievable "sea-island" microstructured zwitterionic-silicone hydrogel devices: augmented oxygen transport and anti-fibrosis for sustaining islet survivalBioact Mater2027 JanPMID 42598441
- IFNα and bleomycin-induced DNA damage activate distinct stress responses in human islets and induced pluripotent stem cell-derived islet cellsIslets2026 Dec 31PMID 42430551
- Is the intraportal or renal subcapsular space a preferable site for islet allo- and xeno-transplantation? A brief historical reviewIslets2026 Dec 31PMID 42017902Review
- MLPH/RAB3A accelerates the differentiation of pancreatic stem cells to islet β-cells to control blood glucose in diabetic ratsOrganogenesis2026 Dec 31PMID 41774510
- Stage-Adapted Disease-Modifying Therapy in Type 1 DiabetesDiabetes Obes Metab2026 NovPMID 42587353Review
- Organotypic vascularization improves maturation of human stem cell-derived islets and restores normoglycemia in diabetic miceCell Stem Cell2026 Oct 16PMID 42887499
- Protective IFIH1 variant reduces islet stress and dysfunction in a type 1 diabetes genetic backgroundiScience2026 Oct 16PMID 42787837
- MenSC-EV-derived HSPA5 activates the AKT/mTOR axis to suppress ferroptosis in type 1 diabetes mellitus-associated ovarian dysfunctionFree Radic Biol Med2026 Oct 13PMID 42869305
- Immune Biomarkers of Islet Transplant Rejection Revealed by Synthetic Immunological NicheAdv Sci (Weinh)2026 Oct 8PMID 42850666
- Oxidative Stress, Post-Translational Modifications, and Type 1 Diabetes PathogenesisImmunol Rev2026 OctPMID 42876362Review
More endocrinology trends
All specialties →Menopausal hormone therapy
Hormone therapy for menopausal symptoms, benefits and risks.
Thyroid eye disease
Thyroid eye disease and targeted treatments such as teprotumumab.
Key point: IGF-1R inhibitors outperformed placebo across multiple thyroid eye disease efficacy outcomes, particularly in active disease, but increased adverse-event risk warrants vigilant monitoring.
CGM in type 2 diabetes
Continuous glucose monitoring for people with type 2 diabetes.
Key point: CGM is strongly recommended for people with type 2 diabetes treated with insulin and those not treated with insulin, particularly when HbA1c is ≥7%.
Anabolic osteoporosis treatment
Romosozumab, abaloparatide and teriparatide for osteoporosis.
Key point: Abaloparatide has efficacy and safety similar to teriparatide and represents a new option for patients with severe osteoporosis and very high fracture risk.
Delaying type 1 diabetes
Teplizumab and other immunotherapy to delay type 1 diabetes.
Once-weekly insulin
Basal insulins given once a week, such as insulin icodec.
Key point: No clinically relevant differences were observed in hypoglycemic event duration or characteristics between once-weekly efsitora and once-daily basal insulin groups.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"type 1 diabetes"[tiab] AND ("stem cell-derived"[tiab] OR "islet transplant*"[tiab] OR "beta cell replacement"[tiab] OR zimislecel[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.